Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 375 shares at $9.27 ($3K) on 2012-06-27, disclosed to the SEC on 2012-06-29.
Scheduled purchase ($3k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.21 | 75 | $691 | 19.9% |
| 2 | $9.27 | 21 | $195 | 5.6% |
| 3 | $9.29 | 100 | $929 | 26.7% |
| 4 | $9.29 | 179 | $2K | 47.8% |
| Total | $9.27 avg | 375 | $3K | 100% |
| Filing → |
| PGNX | BUY | 2013-01-23 | $3K | — | Filing → |
| PGNX | BUY | 2012-12-26 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-30 | $3K | — | Filing → |